AUTHOR=Hensley Mark , Lengfeld Justin , Stoesz Steven , Edwards Michelle , Pass Franklin , Hirst Gillian L. , Brown-Swigart Lamorna , van ‘t Veer Laura , Esserman Laura J. , Beckwith Heather , Yee Douglas 

TITLE=Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial

JOURNAL=Frontiers in Oncology

VOLUME=Volume 15 - 2025

YEAR=2025

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2025.1605120

DOI=10.3389/fonc.2025.1605120

ISSN=2234-943X

ABSTRACT=PurposeDrugs targeting human epidermal growth factor receptor 2 (HER2) have fundamentally changed the way breast cancer is treated. Measurement of HER2 expression has become increasingly important with the approval of therapies targeting a HER2-low population. Furthermore, predictive biomarkers for HER2 response would aid the clinical use of these drugs, and a blood-based assay of HER2 could provide important information for therapeutic options for patients.MethodsTo evaluate serum HER2 (sHER2) as a potential biomarker for breast cancer response, we examined the serum samples from patients treated with neratinib or trastuzumab combined with paclitaxel obtained from the I-SPY2 neoadjuvant trial. This trial included both HER2-positive and HER2-negative/low tumors.ResultsOf the patients with HER2-negative tumors, 26% had elevated sHER2, while 56% of the HER2-positive patients had elevated sHER2. The sHER2 levels declined with neoadjuvant therapy, and most patients had a clinical response to therapy. However, the sHER2 decline was not predictive of pathologic complete response.ConclusionsHER2 was detected in patients with HER2 tissue-positive and tissue-negative tumors. Further study will be needed to determine whether sHER2 is associated with patients with tumors that are HER2-low or ultralow and whether changes in sHER2 over time could predict response to HER2-targeted drugs.Clinical Trial Registrationclinicaltrails.gov, identifier NCT01042379.